Expressing support for the designation of March as "Multiple System Atrophy Awareness Month" to strengthen public awareness of this neurodegenerative disorder.
Summary
H. Res. 1117 is a nonbinding House resolution expressing support for designating March as “Multiple System Atrophy Awareness Month.” The resolution describes Multiple System Atrophy (MSA) as a rare, often fatal neurodegenerative disorder that affects movement, speech, eating, and breathing, and notes that it is frequently misdiagnosed as Parkinson’s disease or progressive supranuclear palsy. It emphasizes that there is no known cure or treatment and that limited public awareness can hinder research and contribute to misdiagnosis.
The resolution also highlights ongoing scientific work, including research at the Multiple System Atrophy Center of Excellence at Stanford School of Medicine, and states that greater awareness and investment in research could improve understanding and help develop therapeutics. In addition to supporting the awareness month designation, the House expresses support for funding research related to MSA in hopes of advancing treatments and, ultimately, a cure.
Impact
Because this is a resolution rather than a bill creating statutory changes, H. Res. 1117 does not directly amend state or federal law or create enforceable rights or obligations. Its practical effect is symbolic and advocacy-oriented: it encourages public awareness, supports recognition of March as an awareness month, and signals congressional support for research funding related to Multiple System Atrophy. The measure primarily affects patients, caregivers, researchers, medical professionals, and advocacy organizations focused on rare neurodegenerative diseases.
Sentiment
The available text reflects a strongly supportive and sympathetic tone toward people affected by Multiple System Atrophy. The resolution frames the disease as serious, under-recognized, and in urgent need of research attention, and it presents awareness-building as a positive step toward better diagnosis and treatment. No votes or committee debate are provided, so there is no evidence of opposition in the record supplied; the overall sentiment appears favorable and consensus-oriented.
Contention
No specific points of contention are identified in the provided materials, and there are no recorded committee transcripts or votes to indicate disagreement. The only potentially debatable element is the resolution’s call for support of research funding, which is aspirational rather than mandatory, but the text itself presents that request as a broadly beneficial public-health measure. Any substantive disagreement would likely center on federal prioritization of rare-disease research funding, though that is not documented here.
A resolution expressing support for the designation of the month of May 2026 as "Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month".